Section 260-70-650. Furosemide.

(1) Furosemide may be administered intravenously to a horse which is entered to compete in a race. Except under the instructions of an official veterinarian for the purpose of removing a horse from the veterinarian's list or to facilitate the collection of a urine sample, furosemide will be permitted only after an official veterinarian has placed the horse on the furosemide or bleeder list.

(2) The use of furosemide is permitted under the following circumstances:

(a) Furosemide must be administered on the grounds of the association, by a single intravenous injection. Administration of furosemide must be no later than three hours prior to post time for the race for which the horse is entered without prior approval of a regulatory veterinarian.

(b) The furosemide dosage administered must not exceed 500 mg nor be less than 150 mg.

(c) The trainer of the treated horse must deliver to an official veterinarian or his/her designee no later than one hour prior to post time for the race for which the horse is entered the following information under oath on a form provided by the commission:

(i) The name of the horse, the horse's tattoo number, racetrack name, the date and time the furosemide was administered to the entered horse;

(ii) The dosage amount of furosemide administered to the entered horse;

(iii) The printed name and signature of the attending licensed veterinarian who administered the furosemide; and

(iv) The signature of the trainer or his/her representative.

(d) Failure to administer furosemide in accordance with these rules may result in the horse being scratched from the race by the stewards.

(e) Test results must show a detectable concentration of the drug in the post-race serum, plasma or urine sample.

(i) The specific gravity of post-race urine samples may be measured to ensure that samples are sufficiently concentrated for proper chemical analysis. The specific gravity must not be below 1.010. If the specific gravity of the urine is found to be below 1.010 or if a urine sample is unavailable for testing, quantitation of furosemide in serum or plasma will be performed;

(ii) Quantitation of furosemide in serum or plasma must be performed when the specific gravity of the corresponding urine sample is not measured or if measured below 1.010. Concentrations may not exceed 100 nanograms of furosemide per milliliter of serum or plasma.

[Statutory Authority: RCW 67.16.020. WSR 16-09-017, § 260-70-650, filed 4/11/16, effective 5/12/16. Statutory Authority: RCW 67.16.020 and 67.16.040. WSR 07-07-036, § 260-70-650, filed 3/12/07, effective 4/12/07; WSR 06-09-009, § 260-70-650, filed 4/10/06, effective 5/11/06; WSR 05-07-067, § 260-70-650, filed 3/11/05, effective 4/11/05. Statutory Authority: RCW 67.16.020. WSR 03-06-004, § 260-70-650, filed 2/20/03, effective 3/23/03. Statutory Authority: RCW 67.16.040. WSR 02-10-102, § 260-70-650, filed 4/30/02, effective 5/31/02; WSR 96-10-001, § 260-70-650, filed 4/17/96, effective 5/18/96.]

RCW 67.16.020. WSR 16-09-017, § 260-70-650, filed 4/11/16, effective 5/12/16. Statutory Authority: RCW 67.16.020 and 67.16.040. WSR 07-07-036, § 260-70-650, filed 3/12/07, effective 4/12/07; WSR 06-09-009, § 260-70-650, filed 4/10/06, effective 5/11/06; WSR 05-07-067, § 260-70-650, filed 3/11/05, effective 4/11/05. Statutory Authority: RCW 67.16.020. WSR 03-06-004, § 260-70-650, filed 2/20/03, effective 3/23/03. Statutory Authority: RCW 67.16.040. WSR 02-10-102, § 260-70-650, filed 4/30/02, effective 5/31/02; WSR 96-10-001, § 260-70-650, filed 4/17/96, effective 5/18/96.